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Coronaviruses are a large family of Coronaviridae 
and a subfamily of Coronavirinae and the order 
Nidovirales that range from the common cold virus to 
the cause of more serious illnesses such as severe acute 
respiratory syndrome (SARS), middle east respiratory 
syndrome (MERS), and severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2). Spherical or 
pleomorphic enveloped particles containing single-
stranded RNA (ssRNA) are associated with a 
nucleoprotein within a capsid comprised of matrix 
protein. The envelope bears club-shaped glycoprotein 
projections [1]. Coronavirus disease 2019 (COVID-19), 
reported on December 31, 2019, in Wuhan, China, 
causes the acute respiratory syndrome. To date, 
thousands of people around the world are infected 
with the virus every day, while the number of people 
who die by COVID-19 is also significant. COVID-19 
disease may manifest either as an asymptomatic 
infection or a mild to severe pneumonia [2]. Due to the 
epidemic of COVID-19 virus in the world, there is an 
urgent need for new antiviral [3]. To date, there is no 
known definitive cure for coronavirus, and no vaccine 
has been developed that is approved by the World 
Health Organization (WHO). Research to date has 
shown that the SARS-CoV-2 and SARS-CoV genes are 
up to 79% identical sequence and their receptor-
binding domain structure are very similar [4]. Both 
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viruses have an animal reservoir and have been 
transmitted from animal to human. SARS was first 
reported in the Guangdong province of southern 
China in 2002 [5].  
As an effort to prevent and inhibit COVID-19 virus 
replication, RNA interference (RNAi) technology can 
be considered. This technology has been previously 
used to turn off the expression of the virus gene in 
SARS-CoV, HIV, HCV, and HBV [6]. RNA 
interference is a process in which double-stranded 
RNA causes a specific sequence in homologous genes 
to be silenced. This natural mechanism for silencing 
specific sequence genes has given biologists hope in 
the treatment of many diseases, including viral 
diseases and cancer, and may have important practical 
applications in agriculture, functional genomics, and 
therapeutic interventions. Historically, RNAi has been 
identified with terms such as repressing or silencing 
genes after transcription. The RNAi mechanism is 
evolutionarily conserved and was found in a wide 
range of eukaryotic organisms [7]. The mechanism of 
RNAi can be accomplished in three ways, including 
synthetic short-interference RNAs (siRNAs; 19-27 
long double-stranded nucleotide RNAs) as well as in 
situ production of short hair RNAs (shRNAs) or 
pointed through plasmid DNA-based expression 
vectors (pDNA). The process of gene deactivation by 
Ahmadi et al. 
2 
RNAi mainly mediated through two small ribonucleic 
acid molecules called microRNA (miRNA) and small 
interfering RNA (siRNA). Specific inhibition of cellular 
mRNA in mammalian cells performed by the 
introduction of synthetic 21- to 23-nucleotide duplexes 
of RNA. Thus, RNAi specifically inhibits gene 
expression and viral genome replication in the host cell 
[8,9]. The RNAi mechanism inhibits gene expression 
in many eukaryotes, including animals. In this process, 
when a double-stranded RNA enters the cytoplasm, it 
is detected by the Dicer enzyme, and fragments of 21 
to 25 nucleotides, known as siRNAs, are produced by 
the enzyme [10]. Then, these short two-string pieces 
will follow different destinies. They may be attached to 
the RNA-induced silencing complex (RISC) set and 
become single-stranded, with one strand separated 
from the whole set by one of the subunits and then 
attached to complementary versions and cut by the 
RISC set. Cleaves transcripts will be degraded by 
cytoplasmic RNases [11]. Good results have been 
obtained in the treatment of SARS virus using RNAi, 
which can be extended to other viruses of the 
coronavirus family. The RNAi strategy has been 
proven to work well in inhibiting different types of 
virus infections such as rotavirus [12], influenza virus 
[13], and HIV-1 [14-15]. In recent years, many studies 
and researches have been done in the treatment of 
SARS through siRNA. The results of most of these 
studies show that all siRNA duplexes specifically 
reduce the expression of the SARS-CoV gene to 
varying degrees compared to the control. Also, it was 
well demonstrated that DNA vector-based siRNA can 
effectively and specifically inhibit the expression of the 
spike protein gene in SARS-CoV cells and inhibit virus 
pathogenicity [6].  
These results suggest that RNAi, as an effective 
antiviral strategy, may be used to inhibit COVID-19 
infection, as previously demonstrated in similar viral 
infections such as SARS, MERS, etc. Since the 
coronavirus is very similar gnomically and structurally 
to the SARS virus, it is to be hoped that RNAi 
technology can be used to control the virus and 
prevent it from becoming pathogenic in humans, thus 
ending this bitter nightmare. Various cellular 
functions, including control of gene expression, 
chromatin status change, and gene silencing, are 
controlled by RNAi pathways. Speed, accuracy, 
economy, targeted transmission, and minimal toxicity 
are some of the factors affecting the therapeutic 
properties of RNAi. Access to methods to identify, 
design, and proprietary pharmaceuticals in the 
process of RNAi, can be considered for the next 
generation of drugs and can also be an effective 
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